PS
LGND icon

Principal Securities’s Ligand Pharmaceuticals LGND Stock Holding History

Principal Securities’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,010
Closed -$202K – 1569
2026
Q1 		$202K Sell
1,010
-117
-10% -$23.1K ﹤0.01% 1383
2025
Q4 		$213K Buy
1,127
+793
+237% +$152K ﹤0.01% 1299
2025
Q3 		$59.2K Buy
334
+58
+21% +$8.62K ﹤0.01% 1873
2025
Q2 		$31.4K Buy
276
+101
+58% +$10.8K ﹤0.01% 2099
2025
Q1 		$18.8K Hold
175
– – ﹤0.01% 2230
2024
Q4 		$18.8K Sell
175
-23
-12% -$2.6K ﹤0.01% 2228
2024
Q3 		$19.8K Buy
198
+151
+321% +$15.2K ﹤0.01% 2129
2024
Q2 		$3.96K Sell
47
-190
-80% -$15.1K ﹤0.01% 2714
2024
Q1 		$17.3K Sell
237
-510
-68% -$37.6K ﹤0.01% 2075
2023
Q4 		$53.4K Buy
+747
New +$44.1K ﹤0.01% 1454

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Securities's LGND Position: Q2 2026 in Review

Principal Securities sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 1,010 shares — an estimated $202K sold.

Principal Securities first reported a position in LGND in Q4 2023 and held it in 10 quarters. The position peaked at $213K in Q4 2025. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Principal Securities reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Principal Securities sold 1,010 Ligand Pharmaceuticals shares in Q2 2026, an estimated $202K.
  • Principal Securities first reported a position in Ligand Pharmaceuticals in Q4 2023 and held it in 10 quarters.
  • Principal Securities's Ligand Pharmaceuticals position peaked at $213K in Q4 2025.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Principal Securities's 13F filing for Q2 2026, filed 4 Aug 2026.